American Association for Cancer Research
Browse
15357163mct190926-sup-229682_2_supp_5998860_q49f2j.docx (503.52 kB)

Supplementary Methods, Supplementary Table 1, and Supplementary Figures 1-4 from SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy

Download (503.52 kB)
journal contribution
posted on 2023-04-03, 18:21 authored by Vincenza Conteduca, Sheng-Yu Ku, Loredana Puca, Megan Slade, Luisa Fernandez, Judy Hess, Rohan Bareja, Panagiotis J. Vlachostergios, Michael Sigouros, Juan Miguel Mosquera, Andrea Sboner, David M. Nanus, Olivier Elemento, Ryan Dittamore, Scott T. Tagawa, Himisha Beltran

Supplementary Information includes: Supplementary Methods, Supplementary Table 1 which shows pathologic and clinical characteristics of patient WCM1388; Supplementary Figure 1 which shows SLFN11 expression across different cancer types; Supplementary Figure 2 which shows CK vs SLFN11 expression in CTCs; Supplementary Figure 3 which shows the discordant case between CTCs and tissue mRNA; Supplementary Figure 4 which is SLFN11 knockout of organoids and response to olaparib

Funding

Prostate Cancer Foundation

Department of Defense

NIH

NCI

History

ARTICLE ABSTRACT

Expression of the DNA/RNA helicase schlafen family member 11 (SLFN11) has been identified as a sensitizer of tumor cells to DNA-damaging agents including platinum chemotherapy. We assessed the impact of SLFN11 expression on response to platinum chemotherapy and outcomes in patients with metastatic castration-resistant prostate cancer (CRPC). Tumor expression of SLFN11 was assessed in 41 patients with CRPC treated with platinum chemotherapy by RNA sequencing (RNA-seq) of metastatic biopsy tissue (n = 27) and/or immunofluorescence in circulating tumor cells (CTC; n = 20). Cox regression and Kaplan–Meier methods were used to evaluate the association of SLFN11 expression with radiographic progression-free survival (rPFS) and overall survival (OS). Multivariate analysis included tumor histology (i.e., adenocarcinoma or neuroendocrine) and the presence or absence of DNA repair aberrations. Patient-derived organoids with SLFN11 expression and after knockout by CRISPR-Cas9 were treated with platinum and assessed for changes in dose response. Patients were treated with platinum combination (N = 38) or platinum monotherapy (N = 3). Median lines of prior therapy for CRPC was two. Median OS was 8.7 months. Overexpression of SLFN11 in metastatic tumors by RNA-seq was associated with longer rPFS compared with those without overexpression (6.9 vs. 2.8 months, HR = 3.72; 95% confidence interval (CI), 1.56–8.87; P < 0.001); similar results were observed for patients with SLFN11-positive versus SLFN11-negative CTCs (rPFS 6.0 vs. 2.2 months, HR = 4.02; 95% CI, 0.77–20.86; P = 0.002). A prostate-specific antigen (PSA) decline of ≥50% was observed in all patients with SLFN11 overexpression. No association was observed between SLFN11 expression and OS. On multivariable analysis, SLFN11 was an independent factor associated with rPFS on platinum therapy. Platinum response of organoids expressing SLFN11 was reduced after SLFN11 knockout. Our data suggest that SLFN11 expression might identify patients with CRPC with a better response to platinum chemotherapy independent of histology or other genomic alterations. Additional studies, also in the context of PARP inhibitors, are warranted.

Usage metrics

    Molecular Cancer Therapeutics

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC